Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 1, 2004, Pages 69-77

  McIntosh, Michelle P ^a,c   Batey, Andrew J ^b,d   Coker, Susan J ^b   Porter, Christopher J H ^a   Charman, William N ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF KANSAS   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOFANTRINE; INTRALIPID; LIPOPROTEIN; LIPOPROTEIN RECEPTOR;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG UPTAKE; HEART MUSCLE; HYPERLIPIDEMIA; HYPOTHESIS; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; POSTPRANDIAL STATE; PROTEIN BINDING; PROTEIN TRANSPORT; QT PROLONGATION; RABBIT;

ANIMALS; ANTIMALARIALS; BLOOD PROTEINS; ELECTROCARDIOGRAPHY; FASTING; FOOD-DRUG INTERACTIONS; LIPOPROTEINS; LONG QT SYNDROME; PHENANTHRENES; POSTPRANDIAL PERIOD; PROTEIN BINDING; RABBITS;

EID: 1042292670     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357022520     Document Type: Article

References (36)

1. Aarons, L. J., Rowland, M. (1981) Kinetics of drug displacement interactions. J. Pharmacokinet. Biopharm. 9: 181-190
2. Batey, A. J., Lightbown, I. D., Lambert, J. P., Edwards, G., Coker, S. J. (1997) Comparison of the acute cardiotoxicity of the antimalarial drug halofantrine in vitro and in vivo in anaesthetized guinea pigs. Br. J. Pharmacol. 122: 563-569
3. Belpaire, F. M., Braeckman, R. A., Bogaert, M. G. (1984) Binding of oxprenolol and propranolol to serum, albumin and alpha-1 acidic glycoprotein in man and other species. Biochem. Pharmacol. 33: 2065-2069
4. Brocks, D. R. (2002) Stereoselective halofantine and desbutyl halofantrine disposition in the rat: Cardiac and plasma concentrations and plasma protein binding. Biopharm. Drug Dispos. 23: 9-15
5. Brocks, D. R., Wasan, K. M. (2002) The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. J. Pharm. Sci. 91: 1817-1826
6. Cenni, B., Meyer, J., Brandt, R., Betschart, B. (1995) The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum. Br. J. Clin. Pharmacol. 39: 519-526
7. Chapman, M. J. (1986) Comparative analysis of mammalian plasma lipoproteins. In: Segrest, J. P., Albers, J. J. (eds) Plasma Lipoproteins. Part A. Preparation, Structure and Molecular Biology. 128th edn, Academic Press, Inc., New York, pp 70-143
8. Coker, S. J. (1989) Anesthetized rabbits as a model for ischemia- and reperfusion-induced arrhythmias: Effects of quinidine and bretylium. J. Pharmacol. Methods 21: 263-279
9. De Groen, P. C. (1988) Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin. Proc. 63: 1012-1021
10. Eder, H. A. (1982) The effect of diet on the transport of probucol in monkeys. Artery 10: 105-107
11. Gillis, A. M., Kates, R. E. (1986) Influence of protein binding on the myocardial uptake and pharmacodynamics of propafenone. J. Cardiovasc. Pharmacol. 8: 1163-1167
12. Giudicelli, C. P., Touze, J. E., Bernard, J. (1996) Electrocardiographic changes in antimalarial treatment with halofantrine, pharmacokinetic study, therapeutic deductions. Bull. Acad. Natl Med. 180: 71-82
13. Humberstone, A. J., Currie, G. J., Porter, C. J. H., Scanlon, M. J., Charman, W. N. (1995) A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. J. Pharm. Biomed. Anal. 13: 265-272
14. Humberstrone, A. J., Porter, C. J. H., Charman, W. N. (1996) A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J. Pharm. Sci. 85: 525-529
15. Humberstone, A.J., Porter, C.J.H., Edwards, G.A., Charman, W.N., (1998a) Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 87: 256-258
16. 50 of halofantrine against Plasmodium falciparum. J. Pharm. Sci. 87: 256-258
17. Karbwang, J., Bangchang, K. N. (1994) Clinical pharmacokinetics of halofantine. Clin. Pharmacokinet. 27: 104-119
18. Karbwang, J., Bangchang, K. N., Bunnag, D., Harinasuta, T., Laothavorn, P. (1993) Cardiac effect of halofantrine. Lancet 342: 501
19. Khoo, S. M., Edwards, G. A., Porter, C. J. H., Charman, W. N. (2001) A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J. Pharm. Sci. 90: 1599-1607
20. Krishna, S., ter Kuile, F. O., Supanaranond, W., Pukrittayakamee S., Teja-Isavatharm, P., Kyle, D. E., White, N. J. (2003) Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br. J. Clin. Pharmacol. 36: 585-591
21. Legg, B., Rowland, M. (1987) Cyclosporin: Measurement of fraction unbound in plasma. J. Pharm. Pharmacol. 39: 599-603
22. Lightbown, I. D., Lambert, J. P., Edwards, G., Coker, S. J. (2001) Potentiation of halofantrine-induced QTc prolongation by mefloquine: Correlation with blood concentrations of halofantrine. Br. J. Pharmacol. 132: 197-204
23. McIntosh, M. P., Porter, C. J. H., Charman, W. N. (1998) The development of an acute post-prandial hyperlipidemia rabbit model. Pharm. Sci. 1: S91
24. McIntosh, M. P., Porter, C. J. H., Wasan, K. M., Ramaswamy, M., Charman, W. N. (1999) Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid. J. Pharm. Sci. 88: 378-384
25. McIntosh, M. P., Batey, A. J., Porter, C. J. H., Charman, W. N., Coker, S. J. (2003) Desbutylhalofantrine: Evaluation of QT prolongations and other cardiovascular effects after intravenous administration in vivo. J. Cardiovasc. Pharmacol. 41: 406-413
26. Milton, K. A., Edwards, G., Ward, S. A., Orme, M. L. E., Breckenridge, A. M. (1989) Pharmacokinetics of halofantrine in man: Effects of food and dose size. Br. J. Clin. Pharmacol. 28: 71-77
27. Monlun, E., Pillet, O., Cochard, J. F., Fararel Garrigues, J. C., Le Bras, M. (1993) Prolonged QT interval with halofantrine. Lancet. 341: 1541-1542
28. Monlun, E., Le Metayer, P., Szwandt, S., Neau, D., Longy, Boursier, M., Horton, R. J., Le Bras, M. (1995) Cardiac complications of halofantrine: A prospective study of 20 patients. Trans. R. Soc. Trop. Med. Hyg. 89: 430-433
29. Nosten, F., ter Kuile, F. O., Luxemburger, C., Woodrow, C., Kyle, D. E., Chongsuphajaisiddhi, T., White, N. J. (1993) Cardiac effects of antimalarial treatment with halofantrine. Lancet 341: 1054-1056
30. Oellerich, M., Muller-Vahl, H. (1984) The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin. Clin. Pharmacokinet. 9 (Suppl. 1): 61-70
31. Snyder, L. R., Kirkland, J. J., Glajch, J. L. (1997) Completing the method: Validation and transfer. In: Snyder, L. R., Kirkland, J. J., Glajch, J. L. (eds) Practical HPLC Method Development 2nd edn, John Wiley and Sons, Inc., New York, pp 687-695
32. Takahashi, S., Kawarabayasi, Y., Nakai, T., Sakai, J., Yamamoto, T. (1992) Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl Acad. Sci. USA 89: 9252-9256
33. Touze, J. E., Bernard, J., Keundjian, A., Imbert, P., Viguier, A., Chaudet, H., Doury, J. C. (1996) Electrocardiographic changes and halofantrine plasma levels during acute falciparum malaria. Am. J. Trop. Med. Hyg. 54: 225-228
34. Wasan, K. M., Cassidy, S. M. (1998) Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87: 411-424
35. Wasan, K. M., Kennedy, A. L., Cassidy, S. M., Ramaswamy, M., Holtorf, L., Chou, J. W., Pritchard, P. H. (1998) Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: Single-dose studies. Antimicrob. Agents Chemother. 42: 3146-3152
36. Woosley, R. L., Siddoway, L. A., Thompson, K., Cerskus, I., Roden, D. M. (1984) Potential applications of free drug level monitoring in cardiovascular therapy. Clin. Pharmacokinet. 9 (Suppl. 1): 79-83